Gyre Therapeutics Inc. (GYRE) — Capital Reinvestment Ratio
Latest as of March 2026:
0.06x
Gyre Therapeutics Inc. (GYRE) has a Capital Reinvestment Ratio of 0.06x as of March 2026, meaning it reinvests 0% of its operating cash flow ($3.18 Million) in capital expenditures ($178.00K). See free cash flow generation of Gyre Therapeutics Inc. to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.06x
Capex / Operating Cash Flow
Operating Cash Flow
$3.18 Million
USD
Capital Expenditures
$178.00K
USD
Data as of
Mar 2026
Most recent filing
Gyre Therapeutics Inc. Capital Reinvestment Ratio (2007–2025)
This chart tracks Gyre Therapeutics Inc.'s Capital Reinvestment Ratio across 5 annual periods.
Annual Capital Reinvestment Ratio for Gyre Therapeutics Inc. (2007–2025)
Year-by-year Capital Reinvestment Ratio for Gyre Therapeutics Inc. from 2007 to 2025. For live market cap and broader valuation context, see GYRE company net worth.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 1.18x | $1.01 Million | $1.19 Million | ▲ +255.3% |
| 2023 | 0.33x | $25.89 Million | $8.59 Million | ▼ -29.2% |
| 2022 | 0.47x | $10.68 Million | $5.00 Million | ▲ +1855.3% |
| 2010 | 0.02x | $138.30 Million | $3.31 Million | ▼ -88.0% |
| 2007 | 0.20x | $24.84 Million | $4.94 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow